Our study suggests that MM relapse (and treatment refractoriness) is associated with an increasing population of activated and exhausted PB CD4 T cells, which may clearly affect the clinical outcome, as shown by the correlation with hypercalcemia, high β2M levels, low albumin levels, a possible association with anemia, and shortened survival. This evidence concerns the gene B2M and hypercalcemia disease.